Abstract
Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management.
Objective: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of pancreatic neuroendocrine tumours.
Methods: A comprehensive literature search strategy was used based on two databases (SCOPUS, and PubMed). We considered all studies published in English, evaluating the use of PRRT (177Luteciuim- DOTA-conjugated peptides and 90Yetrium- DOTA- conjugated peptides) in the treatment of pancreatic neuroendocrine tumours as a standalone entity or as a subgroup within the wider category of Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs).
Results: PRRT was found to be an effective treatment modality as a monotherapy or in combination with other therapies in the treatment of non-operable and metastatic pNETs where other options are limited. Complete response was reported to be between 2-6% while partial response was achieved in up to 60% of cases. Survival analysis was also impressive. Progression Free Survival (PFS) reached a mean of 34 months and Overall Survival (OS) of 53 months. PRRT also proved to improve patients’ Quality of Life (QoL). Acute and sub-acute side effects like nephrotoxicity and haematotoxicity are usually mild and reversible.
Conclusion: PRRT is well tolerated and effective treatment option for non-operable and/or metastatic pNETs. Side effects are usually mild and reversible. Larger randomized controlled trails need to be done to compare PRRT with other treatment modalities and to provide more detailed guidelines regarding patient selections, the choice of PRRT, follow up and response assessment to maximum potential benefit.
Keywords: PRRT, pancreatic neuroendocrine tumours, 177Lu-Dotatate, 90Y-Dotatate, SSTR 1-5, 68Ga-Dotatate PET/CT.
Graphical Abstract
[1]
Zaknun, J.J.; Bodei, L.; Mueller-Brand, J.; Pavel, M.E.; Baum, R.P.; Hörsch, D.; O’Dorisio, M.S.; O’Dorisiol, T.M.; Howe, J.R.; Cremonesi, M.; Kwekkeboom, D.J. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(5), 800-816.
[3]
Public Health England publishes NET data. http://www.ukinets.org/2016/10/public-health-england-publishes-net-data/ (accessed Dec 30, 2018).
[4]
Dromain, C.; Déandréis, D.; Scoazec, J-Y.; Goere, D.; Ducreux, M.; Baudin, E.; Tselikas, L. Imaging of neuroendocrine tumors of the pancreas. Diagn. Interv. Imaging, 2016, 97(12), 1241-1257.
[5]
Zhou, B.; Zhan, C.; Ding, Y.; Yan, S.; Zheng, S. Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: A systematic review and meta-analysis. OncoTargets Ther., 2018, 11, 975-982.
[6]
Goglia, U.; Ferone, D.; Sidoti, M.; Spaziante, R.; Dadati, P.; Ravetti, J-L.; Villa, G.; Bodei, L.; Paganelli, G.; Minuto, F.; Giusti, M. Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. Pituitary, 2007, 11(1), 93-102.
[7]
Taïeb, D.; Garrigue, P.; Bardiès, M.; Abdullah, A.E.; Pacak, K. Application and dosimetric requirements for gallium-68-labeled somatostatin analogues in targeted radionuclide therapy for gastroenteropancreatic neuroendocrine tumors. PET Clin., 2015, 10(4), 477-486.
[8]
Vinik, A. Advances in diagnosis and treatment of pancreatic neuroendocrine tumors. Endocr. Pract., 2014, 20(11), 1222-1230.
[9]
Pelosi, G.; Sonzogni, A.; Harari, S.; Albini, A.; Bresaola, E.; Marchiò, C.; Massa, F.; Righi, L.; Gatti, G.; Papanikolaou, N.; Vijayvergia, N.; Calabrese, F.; Papotti, M. Classification of pulmonary neuroendocrine tumors: New insights. Transl. Lung Cancer Res., 2017, 6(5), 513-529.
[10]
Schnabel, P.; Junker, K. Der. Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds? Pathologe, 2015, 36(3), 283-292.
[11]
Yusuf, S.; Alsadik, S.; Al-Nahhas, A. Peptide receptor radionuclide therapy for neuroendocrine tumours. Clin. Transl. Imaging, 2018, 6(2), 101-111.
[12]
Scoazec, J-Y.; Couvelard, A. Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann. Pathol., 2017, 37(6), 444-456.
[13]
Dromain, C.; Baere, T.D.; Baudin, E.; Galline, J.; Ducreux, M.; Boige, V.; Duvillard, P.; Laplanche, A.; Caillet, H.; Lasser, P.; Schlumberger, M.; Sigal, R. Detection of hepatic metastases from neuro-endocrine tumors with MR imaging: Comparing four different techniques. Am. J. Roentgenol., 2003, 180(1), 121-128.
[14]
Rösch, T.; Lorenz, R.; Braig, C.; Classen, M. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N. Engl.J. Med., 1992, 24(S 1), 304-308.
[15]
Paulson, E.K.; Mcdermott, V.G.; Keogan, M.T.; Delong, D.M.; Frederick, M.G.; Nelson, R.C. Carcinoid metastases to the liver: Role of triple- phase helical CT. Radiology, 1998, 206(1), 143-150.
[16]
Reubi, J.C.; Schär, J-C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J.S.; Mäcke, H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med., 2000, 27(3), 273-282.
[17]
Gabriel, M.; Decristoforo, C.; Kendler, D.; Dobrozemsky, G.; Heute, D.; Uprimny, C.; Kovacs, P.; Guggenberg, E.V.; Bale, R.; Virgolini, I.J. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med., 2007, 48(4), 508-518.
[18]
Shi, C.; Gonzalez, R.S.; Zhao, Z.; Koyama, T.; Cornish, T.C.; Hande, K.R.; Walker, R.; Sandler, M.; Berlin, J.; Liu, E.H. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Am. J. Clin. Pathol., 2015, 143(3), 398-404.
[19]
Zen, Y.; Heaton, N. Elevated Ki-67 labeling index in ‘synchronous liver metastases’ of well differentiated enteropancreatic neuroendocrine tumor. Pathol. Int., 2013, 63(11), 532-538.
[22]
Hosono, M.; Ikebuchi, H.; Nakamura, Y.; Nakamura, N.; Yamada, T.; Yanagida, S.; Kitaoka, A.; Kojima, K.; Sugano, H.; Kinuya, S.; Inoue, T.; Hatazawa, J. Manual on the proper use of lutetium-177-
labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in
radionuclide therapy Ann. Nucl. Med, 2nd ed.; , 2018, 32, pp. (3)217-235.
[23]
Mojtahedi, A.; Thamake, S.; Tworowska, I. Ranganathan, D.; Delpassand, E.S. The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: A review of literature. Am. J. Nucl. Med. Mol. Imaging, 2014, 4(5), 426-434.
[24]
Toumpanakis, C.; Kim, M.K.; Rinke, A.; Bergestuen, D.S.; Thirlwell, C.; Khan, M.S.; Salazar, R.; Oberg, K. Combination of crosssectional and moleculari maging studies inthelocalization of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology, 2014, 99(2), 63-74.
[25]
Goglia, U.; Ferone, D.; Sidoti, M.; Spaziante, R.; Dadati, P.; Ravetti, J-L.; Villa, G.; Bodei, L.; Paganelli, G.; Minuto, F.; Giusti, M. Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. Pituitary, 2007, 11(1), 93-102.
[26]
Vliet, E.I.V.; Eijck, C.H.V.; Krijger, R.R.D.; Dijkum, E.J.N.V.; Teunissen, J.J.; Kam, B.L.; Herder, W.W.D.; Feelders, R.A.; Bonsing, B.A.; Brabander, T.; Krenning, E.P.; Kwekkeboom, D.J. Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3] octreotate. J. Nucl. Med., 2015, 56(11), 1647-1653.
[27]
Stoeltzing, O.; Loss, M.; Huber, E.; Gross, V.; Eilles, C.; Mueller-Brand, J.; Schlitt, H.J. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchro- nous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch. Surg., 2009, 395(2), 185-192.
[28]
Campana, D.; Nori, F.; Piscitelli, L.; Morselli-Labate, A.M.; Pezzilli, R.; Corinaldesi, R.; Tomassetti, P. Chromogranin A: is it a useful marker of neuroendocrine tumors? J. Clin. Oncol., 2007, 25(15), 1967-1973.
[29]
Mestier, L.D.; Dromain, C.; Dassignies, G.; Scoazec, J-Y.; Lassau, N.; Lebtahi, R.; Brixi, H.; Mitry, E.; Guimbaud, R.; Courbon, F.; Dherbomez, M.; Cadiot, G. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr. Relat. Cancer, 2013, 21(3)
[30]
Anthony, L.B.; Woltering, E.A.; Espenan, G.D.; Cronin, M.D.; Maloney, T.J.; Mccarthy, K.E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin. Nucl. Med., 2002, 32(2), 123-132.
[31]
Valkema, R.; Jong, M.D.; Bakker, W.H.; Breeman, W.A.; Kooij, P.P.; Lugtenburg, P.J.; Jong, F.H.D.; Christiansen, A.; Kam, B.L.; Herder, W.W.D.; Stridsberg, M.; Lindemans, J.; Ensing, G.; Krenning, E.P. Phase I study of peptide receptor radionuclide therapy with 111In-DTPA]octreotide: The rotterdam experience. Semin. Nucl. Med., 2002, 32(2), 110-122.
[32]
Zwan, W.A.V.D.; Bodei, L.; Mueller-Brand, J.; Herder, W.W.D.; Kvols, L.K.; Kwekkeboom, D.J. GEPNETs update: Radionuclide therapy in neuroendocrine tumors. Eur. J. Endocrinol., 2015, 172(1), 1-8.
[33]
Romer, A.; Seiler, D.; Marincek, N.; Brunner, P.; Koller, M.T.; Ng, Q.K.T.; Maecke, H.R.; Müller-Brand, J.; Rochlitz, C.; Briel, M.; Schindler, C.; Walter, M.A. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y- DOTA]-TOC in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2014, 4(2), 214-222.
[34]
Villard, L.; Romer, A.; Marincek, N.; Brunner, P.; Koller, M.T.; Schindler, C.; Ng, Q.K.; Mäcke, H.R.; Müller-Brand, J.; Rochlitz, C.; Briel, M.; Walter, M.A. Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers. J. Clin. Oncol., 2012, 30(10), 1100-1106.
[35]
Bodei, L.; Mueller-Brand, J.; Baum, R.P.; Pavel, M.E.; Hörsch, D.; O’Dorisio, M.S.; O’Dorisio, T.M.; Howe, J.R.; Cremonesi, M.; Kwekkeboom, D.J.; Zaknun, J.J. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2013, 41(3), 584-584.
[36]
O’Toole, D.; Kianmanesh, R.; Caplin, M. ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology, 2016, 103(2), 117-118.
[37]
Falconi, M.; Eriksson, B.; Kaltsas, G.; Bartsch, D.; Capdevila, J.; Caplin, M.; Kos-Kudla, B.; Kwekkeboom, D.; Rindi, G.; Klöppel, G.; Reed, N.; Kianmanesh, R.; Jensen, R. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2016, 103(2), 153-171.
[38]
Mestier, L.D.; Dromain, C.; Dassignies, G.; Scoazec, J-Y.; Lassau, N.; Lebtahi, R.; Brixi, H.; Mitry, E.; Guimbaud, R.; Courbon, F.; Dherbomez, M.; Cadiot, G. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr. Relat. Cancer, 2013, 21(3), R105-R120.
[39]
Ezziddin, S.; Khalaf, F.; Vanezi, M.; Haslerud, T.; Mayer, K.; Zreiqat, A.A.; Willinek, W.; Biersack, H-J.; Sabet, A. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(5), 925-933.
[40]
Kwekkeboom, D.J.; Herder, W.W.D.; Kam, B.L.; Eijck, C.H.V.; Essen, M.V.; Kooij, P.P.; Feelders, R.A.; Aken, M.O.V.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol., 2008, 26(13), 2124-2130.
[41]
Imhof, A.; Brunner, P.; Marincek, N.; Briel, M.; Schindler, C.; Rasch, H.; Mäcke, H.R.; Rochlitz, C.; Müller-Brand, J.; Walter, M.A. Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue 90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. J. Clin. Oncol., 2011, 29(17), 2416-2423.
[42]
Valkema, R.; Pauwels, S.; Kvols, L.K.; Barone, R.; Jamar, F.; Bakker, W.H.; Kwekkeboom, D.J.; Bouterfa, H.; Krenning, E.P. Survival and Response After Peptide Receptor Radionuclide Therapy With 90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors. Semin. Nucl. Med., 2017, 36(2), 147-156.
[43]
Sansovini, M.; Severi, S.; Ambrosetti, A.; Monti, M.; Nanni, O.; Sarnelli, A.; Bodei, L.; Garaboldi, L.; Bartolomei, M.; Paganelli, G. Treatmrnt with radiolabelledsomatostatin analog 177Lu-Dotatate for advanced pancreatic neuroendocrine tumors. Neuroendocrinology, 2013, 97(4), 347-354.
[44]
Bushnell, D.L.; Odorisio, T.M.; Odorisio, M.S.; Menda, Y.; Hicks, R.J.; Cutsem, E.V.; Baulieu, J-L.; Borson-Chazot, F.; Anthony, L.; Benson, A.B.; Oberg, K.; Grossman, A.B.; Connolly, M.; Bouterfa, H.; Li, Y.; Kacena, K.A.; Lafrance, N.; Pauwels, S.A. 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide. J. Clin. Oncol., 2010, 28(10), 1652-1659.
[45]
Pfeifer, A.K.; Gregersen, T.; Grønbæk, H.; Hansen, C.P.; Müller-Brand, J.; Bruun, K.H.; Krogh, K.; Kjær, A.; Knigge, U. Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland. Neuroendocrinology, 2011, 93(3), 189-196.
[46]
Cwikla, J.B.; Sankowski, A.; Seklecka, N.; Buscombe, J.R.; Nasierowska-Guttmejer, A.; Jeziorski, K.G.; Mikolajczak, R.; Pawlak, D.; Stepien, K.; Walecki, J. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): A phase II study. Ann. Oncol., 2009, 21(4), 787-794.
[47]
Barber, T.; Hofman, M.; Thomson, B.; Hicks, R. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur. J. Surg. Oncol., 2012, 38(1), 64-71.
[48]
Bettini, R.; Partelli, S.; Boninsegna, L.; Capelli, P.; Crippa, S.; Pederzoli, P.; Scarpa, A.; Falconi, M. Tumor size correlate with malignancy in nonfunctionning pancreatic endocrine tumor. Surgery, 2011, 150(1), 75-82.
[49]
Takumi, K.; Fukukura, Y.; Higashi, M.; Ideue, J.; Umanodan, T.; Hakamada, H.; Kanetsuki, I.; Yoshiura, T. Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur. J. Radiol., 2015, 84(8), 1436-1443.
[50]
Brabander, T.; Teunissen, J.; Van Eijck, C.; Franssen, G.; Feelders, R.; Herder, W.; Kwekkeboom, D. Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Pract. Res. Clin. Endocrinol. Metab., 2016, 30(1), 103-114.
[51]
Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P.L.; Kulke, M.H.; Jacene, H.; Bushnell, D.; O’Dorisio, T.M.; Baum, R.P.; Kulkarni, H.R.; Caplin, M.; Lebtahi, R.; Hobday, T.; Delpassand, E.; Cutsem, E.V.; Benson, A.; Srirajaskanthan, R.; Pavel, M.; Mora, J.; Berlin, J.; Grande, E.; Reed, N.; Seregni, E.; Öberg, K.; Sierra, M.L.; Santoro, P.; Thevenet, T.; Erion, J.L.; Ruszniewski, P.; Kwekkeboom, D.; Krenning, E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N. Engl. J. Med., 2017, 376(2), 125-135.
[52]
Keizer, B.D.; Aken, M.O.V.; Feelders, R.A.; Herder, W.W.D.; Kam, B.L.R.; Essen, M.V.; Krenning, E.P.; Kwekkeboom, D.J. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(4), 749-755.
[53]
Melis, M.; Krenning, E.P.; Bernard, B.F.; Barone, R.; Visser, T.J.; Jong, M.D. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32(10), 1136-1143.
[54]
Kwekkeboom, D.J.; Krenning, E.P.; Scheidhauer, K.; Lewington, V.; Lebtahi, R.; Grossman, A.; Vitek, P.; Sundin, A.; Plöckinger, U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology, 2009, 90(2), 184-189.
[55]
Valkema, R.; Pauwels, S.; Kvols, L.A.; Kwekkeboom, D.; Jamar, F.; de Jong, M.; Barone, R.; Walrand, S.; Kooij, P.; Bakker, W.; Lasher, J.; Krenning, E. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J. Nucl. Med., 2005, 46(Suppl. 1), 83S-91S.
[56]
Bodei, L.; Cremonesi, M.; Ferrari, M.; Pacifici, M.; Grana, C.M.; Bartolomei, M.; Baio, S.M.; Sansovini, M.; Paganelli, G. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(10), 1928-1928.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Cancer Genes
Cancer Medicine in an Ayurvedic Perspective: A Critical Overview
Cancer Genes
Anticancer Immunity: Reviewing the Potential of Probiotics
Probiotics in Anticancer Immunity
Phytonutrients in the Treatment of Gastrointestinal Cancer
Molecular Targets and Cancer Therapeutics (Part 2)
Molecular Targets and Cancer Therapeutics (Part 1)
Article Metrics
62
4
1
3